Author: AMP GCG

Home / Articles posted by AMP GCG
Posted on January 11, 2021
Press Release

ERFURT/BERLIN, Germany, January 11th, 2021 – AMP German Cannabis Group Inc. (“AMP” and or “the Company”) (CSE: XCX), (Frankfurt: C4T, ISIN: CA00176G1028) announces its intention to change its corporate name to AMP Alternative Medical Products Inc. The new corporate name aligns with AMP’s brand name and logo for medical and wellness cannabis products, which AMP will be launching for sale in Germany this quarter. The Company’s trading symbol on the Canadian Securities Exchange will not change. The Company...

by
0
Posted on December 16, 2020
Press Release

ERFURT/BERLIN, Germany, December 16th, 2020 – AMP German Cannabis Group Inc. (“AMP”) (CSE: XCX), (Frankfurt: C4T, ISIN: CA00176G1028) is pleased to provide a letter to its shareholders. Dear Shareholders, The upcoming year will be transformational for AMP and the medical cannabis industry in Germany and globally. AMP’s focus has always been to supply German patients with the highest quality cannabis products available. Our strength is having front-line relationships with the distributors of medical cannabis to pharmacies, the only point-of-sale for...

by
0
Posted on November 30, 2020
Press Release

ERFURT and BERLIN, Germany, November 30th, 2020 – AMP German Cannabis Group Inc. (“AMP”) (CSE: XCX) (FSE: C4T, ISIN: CA00176G1028) is proud to present the second episode of its "Round Table" series with Dr. Wieland Schinnenburg, MdB of the FDP, who provides an up-to-date overview of the political issues and challenges facing the medical cannabis in Germany. In addition, the discussion panel will share their views on how the industry will change for companies operating in the sector over the...

by
0
Posted on November 5, 2020
Press Release

ERFURT / BERLIN, Germany, and ÅRSLEV, Denmark – November 5th, 2020 – AMP German Cannabis Group Inc. (“AMP”) (CSE: XCX), (Frankfurt: C4T, ISIN: CA00176G1028), providing German patients with a wide range of pharmaceutical grade medical cannabis products and Schroll Medical ApS (“Schroll”), a Danish cultivator of medical cannabis, announce that they have entered into a non-exclusive, three-year supply agreement for bulk and packaged EU-GMP cannabis flower which shall be branded under the AMP medical cannabis brand when offered in the...

by
0
Posted on October 22, 2020
Press Release

ERFURT / BERLIN, Germany, and Perth, Western Australia - October 22nd, 2020 – AMP German Cannabis Group Inc. (“AMP”) (CSE: XCX), (Frankfurt: C4T, ISIN: CA00176G1028), providing German patients with a wide range of pharmaceutical grade medical cannabis products, is pleased to announce it will be adding Little Green Pharma Ltd. (ASX: LGP) cannabis oil medicines to its catalogue for sale in Germany beginning in November 2020 subject to obtaining a BtM-registration (narcotic drug licence) of these products on behalf of...

by
0
Posted on October 19, 2020
Press Release

ERFURT and BERLIN, Germany, October 19th, 2020 – AMP German Cannabis Group Inc. (“AMP” or the “Company”) (CSE: XCX), (FSE: C4T, ISIN: CA00176G1028), providing German patients with a wide range of pharmaceutical grade medical cannabis products, announces that it has granted incentive stock options to purchase 590,000 common shares of the Company to an officer and employees in accordance with its stock option plan. Each option vests immediately, has an exercise price of C$0.35 per share and expires on September 8,...

by
0
Posted on October 9, 2020
Press Release

ERFURT and BERLIN, Germany, October 9th, 2020, AMP German Cannabis Group Inc. (“AMP”) (CSE: XCX), (Frankfurt: C4T, ISIN: CA00176G1028), a licenced importer of medical cannabis into Germany, announces that its previously announced non-brokered private placement financing has been increased due to strong investor demand. The private placement was originally announced on September 8, 2020, with the anticipation of raising gross proceeds of $500,000 at a price of $0.35 per share. The private placement was oversubscribed, and a total of approximately $771,956...

by
0
Posted on September 18, 2020
Press Release

ERFURT and BERLIN, Germany - September 18, 2020 – AMP German Cannabis Group Inc. (“AMP”) (CSE: XCX), (Frankfurt: C4T, ISIN: CA00176G1028), announces it has closed the first tranche of its non-brokered private placement announced on September 9th, 2020. Under the first tranche, AMP raised gross proceeds of $390,525 through the issuance of 1,115,785 common shares at a subscription price of $0.35 per share and are subject to a four month hold period.  AMP paid a finders’ fee of $1,715 and...

by
0
Posted on September 15, 2020
Press Release

ERFURT and BERLIN, Germany - September 15th, 2020 – AMP German Cannabis Group Inc. (“AMP”) (CSE: XCX), (Frankfurt: C4T, ISIN: CA00176G1028), a licenced importer of medical cannabis into Germany, is pleased to announce the appointment of Mr. Marc Wälken as Sales Director, effective immediately. Mr. Wälken joins AMP from Spectrum Therapeutics, a brand of Canopy Growth Germany GmbH, a wholly-owned subsidiary of Canopy Growth Corporation (TSX: WEED), one of the largest importers of medical cannabis into Germany, where he was Areas...

by
0
Posted on September 10, 2020
Press Release

ERFURT and BERLIN, Germany, September 10th, 2020 – AMP German Cannabis Group Inc. (“AMP” or the “Company”) (CSE: XCX) (FSE: C4T, ISIN: CA00176G1028), a licenced importer of medical cannabis into Germany, provides a strategy update on how it plans to supply Germany with EU-GMP medical cannabis products continuously. AMP purchases EU-GMP medical cannabis and imports it through its supply chain management system to Germany and sells directly to pharmacists, the only point of sale to German patients with a physician’s prescription...

by
0